The single greatest Breast Cancer risk factor

JULY 24, 2010 By Robert Graham -- Washington, DC



The single greatest Breast Cancer risk factor is a family history of the disease.
Autosomal dominant inheritance of breast cancer is characterized by
transmission of cancer predisposition from generation to generation,
With the Increased use of preoperative MRI may play a role, but mastectomy rates also
rose in women not undergoing preoperative MRI.Mastectomy rates
have been on the upswing at the Mayo Clinic in Rochester, Minnesota,
and researchers cited MRI as a factor influencing the increase.


Inheritance risk of 50%. When a parent carries an autosomal dominant genetic
predisposition, each child has a 50:50 chance of inheriting the predisposition.

Both males and females can inherit and transmit an autosomal dominant
cancer predisposition. A male who inherits a cancer predisposition and shows
no evidence of it can still pass the altered gene on to his sons and daughters

One of the ways to be sure that a Mastectomy is the way to go is genomics
Genomics is the study of the human cancer genome. It is a search within
"cancer families" and patients for the full collection of genes and
mutations--both inherited and sporadic--that contribute to the development
of a cancer cell and its progression from a localized cancer to one that grows
uncontrolled and metastasizes (spreads throughout the body).


To Educate Oncologist and Breast Cancer Patients and in rural areas,is to incorporate
TeleMedicine using Wireless BroadBand Spectrum that President Obama has given the FCC
the okay allocate to customers in Rural areas. Others technologies will help Breast Cancer
Patients Make better treatment choices is listed below

Cloud computing:

• Worldwide revenue from public IT cloud services exceeded $16 billion in 2009

Software as a Service:

• SaaS = 73% of public Cloud services revenue in 2009
• Forecasted to reach $55.5B in 2014, with a CAGR of 27.4%
• Public IT cloud will be over 25% of the net-new growth in traditional IT
• products between now and 2014.

It is clear to Hybrid Medical Analytics that we can help Oncologist help their Breast
Cancer Patients.

PRESIDENT CLINTON ANNOUNCES HUMAN GENOME June 26, 2000

JULY 14, 2010 By Robert Graham --
PRESIDENT CLINTON ANNOUNCES THE COMPLETION OF THE FIRST

SURVEY OF THE ENTIRE HUMAN GENOME Hails Public and Private Efforts Leading to This Historic Achievement
June 26, 2000

A historic White House event with British Prime Minister Tony
Blair, President Clinton announced that the international Human Genome Project and Celera Genomics Corporation have both completed an initial sequencing of the human genome -- the genetic blueprint for human beings.

Genomics Science and Broad Band will Reduce Breast Cancer in Rural Areas After H.R.5440: Genomics and Personalized Medicine Act of 2010 - U.S passes.

JULY 2, 2010 U.S. President Barack Obama announce new American Recovery and Reinvestment Act broad band projects.

July 12th 2010 Steve Ballmer outlined how cloud computing is
transforming IT. Bob Muglia announced the Windows Azure Appliance. Tami Reller detailed the partner opportunity with Windows 7.

July 14 2010 Hybrid Medical Analytic CIO -Microsoft Can Help President Obama Create 100,000 Jobs in Rural Areas with Microsoft's Partner Program .

Today's Microsoft is equip to Assist Small Business grow with several New Programs like Microsoft New Certification.

The Ingredients is there to put America's High Tech Workers back
to Work. Retrained in Bio Tech Engineering.

Microsoft is showing that their Preoccupations and Obsessions of being the Best in the world is on Display at The Microsoft Worldwide Partner Conference 2010 held on July 11-15, 2010, at the Walter E. Washington Convention Center, Washington D.C., USA.Thefive-day partner event of the year offers you the opportunity to learn about Microsoft's roadmap and best
practices for the year. You will gain exclusive access to
networking with Microsoft executives and other partners.
You will explore the infinite opportunities with Microsoft's
cloud computing strategy to take your business to the next
level and gain an edge on your competition.


Mircosoft Partners are as strong as they have ever been, Hybrid
Medical has Named this years "Best of show" to iLink System From
Remond,WA. Take a Look at the Video to See Why.

Microsoft has Named Slalom Consulting Seattle, WA as Partner
of the Year. Take Look at this Video of Slalom at their Party
at Long View Gallaery in Washington DC.

Hybrid Medical Analytics has identified The Vertical Market that
Partners can use to grown their Partnerships. Health Care It combine with Genomics, Personalized Medicines, President Obama Broad Band for Rural Areas and Sharepoint can create over 100,000 Jobs in Rural America.

The WPC 2010 EXPO includes:

The newest products and services from Microsoft, including
Windows 7 and Office 2010.
The latest information about Cloud Services - build
solutions in the Cloud to bring businesses online.
Experts demonstrating the latest and greatest
in end-to-end solutions for the IT sector.
Presentations at the Expo Theater Live Stage.

Over 100 interactive sessions and over 170 Exhibitions.


If you are in IT and is not Here you are missing The Best in the World

Regenerative medicine company that uses induced pluripotent stem (iPS) cells, has raised $22 million.

JULY 10, 2010 By Robert Graham -- Regenerative medicine
company that uses induced pluripotent stem (iPS) cells, has
raised $22 million.

Hybrid Medical Analytics Research has shown genomics, pluripotent stem (iPS) cells is the Future for Treating Breast Cancer along with Bacteria process called quorum sensing.

Bacteria communicate with one another using chemical signal
molecules. As in higher organisms, the information supplied by these molecules is critical for synchronizing the activities of large groups of cells. In bacteria, chemical communication involves producing, releasing,detecting, and responding to small hormone-like molecules termed autoinducers. This process, termed quorum sensing, allows bacteria to monitor the environment for other bacteria and to alter behavior on a population-wide scale in response to changes in the number and/or species present in a community. Most quorumsensing-
controlled processes are unproductive when undertaken by
an individual bacterium acting alone but become beneficial when carried out simultaneously by a large number of cells. Thus, quorum sensing confuses the distinction between prokaryotes and eukaryotes because it enables bacteria to act as multicellular organisms. This review focuses on the architectures of bacterial chemical communication networks; how chemical information is integrated, processed, and transduced to control gene expression; how intra- and interspecies cell-cell communication is ccomplished; and the intriguing possibility of prokaryote-eukaryote cross-communication.


Regenerative medicine company that uses induced pluripotent
stem (iPS) cells, has raised $22 million in Series B funding. Google Ventures led the round, and was joined by Mitsubishi UFJ Capital, ATEL Ventures and return backers MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

The company has perfected a difficult technology and is making excellent progress in finding new therapeutics to treat serious diseases,” said Dr. Yeshwant. ”The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will ramatically improve the drug discovery and development process, and we look forward to helping them accomplish their mission.”

Hybrid Medical Analytics has been and will be a Leader in this space.

H.R. 5440, The Genomics and Personalized Medicine Act of 2010

H.R. 5440, The Genomics and Personalized Medicine Act of 2010

H.R. 5440 would secure the promise of personalized medicine for
all Americans by expanding and accelerating genomics research and
initiatives to improve the accuracy of disease diagnosis, increase
the safety of drugs, and identify novel treatments.
Hybrid Pharmaceutical has just returned from Israel for the Personalized Medicine world Conference
Conference and Discover that the 111th Congress has a Genomics personalized medicine
Bll. This is super great news for Breast Cancer Patients

SEC. 301. GENOMICS AND PERSONALIZED MEDICINE EDUCATION AND TRAINING.

(a) In General- The Secretary shall make grants, contracts, or cooperative
agreements to eligible entities to improve the adequacy of genomics and personalized
medicine training for specimen collection, diagnosis, treatment, and counseling of
adults and children for both rare and common disorders, through support of efforts to--

(1) develop and disseminate model education and training programs across
all health professionals, including medical student, graduate medical, and continuing
education, that reflect the new knowledge and evolving practice of genetics and genomics
including the appropriate use of products used in personalized medicine;

(2) assist with the review of board and other certifying examinations
by professional societies and accreditation bodies to ensure adequate focus on the
fundamental principles of genomics and personalized medicine and applications to
clinical decisionmaking;


(3) identify, evaluate, and develop options for distance or online learning
for degree or continuing education programs;

(4) identify gaps and opportunities to strengthen continuing
education programs for health care professionals;

(5) develop and disseminate model programs to train pathologists
on the specialized mechanisms of collection and storage of human biological
specimens for biobanks; and

(6) develop exchange programs for student, residents, and fellows
to learn techniques and practices to augment genomics and personalized medicine.




SEC. 401. REDUCING THE REDUNDANCY OF CLINICAL LABORATORY REQUIREMENTS.

(a) In General- The Secretary, acting through the Administrator of the Centers
for Medicare & Medicaid Services and the Commissioner of Food and Drugs, shall establish
a committee to carry out a comparative analysis of laboratory review requirements under
CLIA to--

(1) assess and reduce unnecessary differences in such requirements; and

(2) identify opportunities to eliminate redundancies and decrease the burden

of review, as practicable, of the Centers for Medicare & Medicaid Services, the Food
and Drug Administration, and private laboratory certifying entities.

(b) Representation- The membership of the committee established under
this section shall include representatives of the agencies of the Public Health
Service, other appropriate Federal departments and agencies, private laboratories,
and private laboratory accreditation organizations.

(c) Public Input- The Secretary shall conduct open public meetings and
develop a process to allow for public comment on such comparative analysis.

The Food and Drug Administration is issuing regulatory letters for Genomic Test

WASHINGTON -- 46th DIA (Drug Information Association) Annual Meeting -- The Food and Drug Administration is regulatory letters for Genomic Test. This is the first sign that the government is recognizing companies like Hybrid Pharmaceutical Inc that use DNA samples to predict Breast Cancer and inheritable diseases.

The FDA letters state that genomics tests are considered
medical devices and must be federally approved as safe
and effective.This is great news for Hybrid Pharmaceuticals
and the nascent personal genomics industry and our customers.

Washington DC has the highest Stage IV Breast Cancer Rate
in the US. A genomic test looks looks at 21 genes in a
patient's breast tumor and how active they are. Our focus is
on Genomic Trials. Genomics Science looks at groups of genes
and how active they are. This activity can influence how
a cancer is likely to grow and respond to treatment. Unlike
a genetic test, that provide information about a person’s
inherited genetic make-up. Instead,Hybrid Pharmaceuticals
looks at 21 genes in a patient’s breast tumor trials to
understand how these genes interact and influence the tumor’s
behavior.

85% of Breast Cancer Patients that get a Genomics Personalized
test will enable Oncologist to recommend that right treatment.
instead of the 50% of Breast Cancer Patients that get Toxic
Chemotherapy.

BR Graham Editor

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics




The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics being added to The Veterans Affairs New VISTA S.O.A stratergy.

Scott Cragg, Special Assistant to the CIO, U.S. Department of Veterans Affairs and his Team.
John Teeter, Deputy Chief Information Officer, Department of Health and Human Services. CAPT Michael Weiner, Chief Medical Officer for the Defense Health Information Management System (DHIMS) Ed Meagher, Director, Strategic Healthcare Initiatives, SRA International; former Deputy Chief Information Officer, Dept. of Veterans Affairs (moderator) made their comments at the
AFFIRM The Association for Federal Information Resources Management ( http://affirm.org/ )May Monthly Luncheon on Health IT

The Department of Veterans affirs has a new System Called Veterans Health Information Systems and Technology Architecture (VISTA) said that they are not Including Genomics as a part of their VISTA system.

Genomics is the study of complex sets of genes, how they are expressed in cells (what their level of activity is), and the role they play in biology. Another way to think about it is as a small network of genes and how they work together to influence the a Veterans Breast CancerTumor's biology and behavior.

VISTA is built on a client-server architecture, which ties together workstations and personal computers with graphical user interfaces at Veterans Health Administration (VHA) facilities, as well as software developed by local medical facility staff. VISTA also includes the links that allow commercial off-the-shelf software and products to be used with existing and future
technologies. The Decision Support System (DSS) and other national databases that might be derived from locally generated data lie outside the scope of VISTA.

Hybrid Medical Analytics Our focus is on Genomic Trials. Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment. Unlike a genetic test, that provide information about a person's inherited genetic make-up. Instead,

Hybrid Medical Analytics looks at 21 genes in a patient's breast tumor trials to understand how these genes interact and influence the tumor's behavior.


Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems


Hybrid Medical Electronic e-Clinicals and early stage trials that allows
us unique insight into the most prevalent challenges at this phase of
testing. We have strategically built an infrastructure, methodology
and facility that meet those needs.

82% Increase in Transgenic R&D for Breast Cancer that is Carcinogenesis caused by Li-Fraumeni Syndrome

82% Increase in Transgenic R&D for Breast Cancer that is carcinogenesis caused by Li-Fraumeni syndrome. Hybrid Medical focused on:

Family history and other risk factors for breast Cancer.
Models for predicting breast cancer risk.
Major genes associated with breast cancer
Screening and risk modification for hereditary breast cancer
Psychosocial issues associated with hereditary breast cancer

Among women, breast cancer is the most commonly diagnosed cancer after nonmelanoma skin cancer.

The syndromes most strongly associated with Breast cancers are BRCA1 or BRCA2 mutation syndromes. Breast cancer is also a common feature of Li-Fraumeni syndrome due to P53 mutations.

Breast Cancer research for a cure has a new friend. P53 or mP53. Mutant in transgenic mice has shown promise in the cure for Breast Cancer. Hybrid Medical e-Clinical generated transgenic
mice carrying mutant p53. We cloned the m53 cDNA from a radiation-induced mouse tumor.

The tumors was treated via a potent atelocollagen suppression of the tumors growth. The Result that mp53 activity caused tumors that can be suppressed by subsequent silencing of the mp53.

This is great news because if you get a Genomics Test and discover that you have Brac1 or Brac2one of the major causes of Breast Cancer, the mP53 Mutant can be suppressed and extend Life

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems